A number of different troubling symptoms and side effects have been associated with the medication Tasigna.

These Tasigna side effects, according to some consumers, were never explained in warnings on the prescription label and left users of the drugs at risk of developing severe and life-changing consequences.

According to those consumers who have taken legal action as a result of their problems with Tasigna, the manufacturers have failed to appropriately disclose the possibility of atherosclerosis, vascular conditions, and peripheral artery disease.

Tasigna is given to patients who have been diagnosed with chronic myelogenous leukemia. This cancer impacts bone marrow and blood cells.

Among the reported side effects of Tasigna treatment are atherosclerosis. Atherosclerosis happens when fats and cholesterol build up on the walls of the arteries. The arteries then become harder and thicker, blocking the full flow of blood. This condition can become dangerous if the patient does not recognize the early signs of this plaque-building.

Problems with Tasigna can include artery issues, artery disease, high blood pressure, muscle weakness, and chest pain. All of these should be reported to a doctor right away.

A growing number of Tasigna lawsuits have highlighted recent research connecting the leukemia medication with arteriosclerosis and related vascular problems. An American Journal of Hematology article published in 2011 explained the situation for 24 patients who were taking Tasigna for the treatment of chronic myelogenous leukemia, also known as CML.

Of that small group of patients, three of them went on to develop peripheral artery disease and related vascular disorders. None of those patients had a previous connection with peripheral artery disease. In 2012, the Blood Medical Journal reported that four out of a group of 27 patients who took Tasigna side effects developed peripheral artery disease and one of those patients suffered a heart attack.

A leukemia journal article published in 2013 reported that those patients using Tasigna for the treatment of CML were more likely to develop peripheral artery disease when compared with other CML medications. Tasigna first came on the market in 2007 and its primary purpose was to replace Gleevac.

Gleevac was set to lose its patent protection in 2015. One of the first Tasigna symptoms lawsuits was filed in March 2016, after a man passed away allegedly due to complications linked to arteriosclerosis shortly after he began using the medication in 2012.

These and other similar lawsuits have argued that the manufacturers failed to disclose the possibility of these problematic side effects. Some of the most common side effects of Tasigna include changes in liver enzymes, itching, constipation, nausea and too few white cells.

Severe side effects for Tasigna CML patients include low calcium, potassium and sodium amounts in the blood, high blood pressure, and high blood sugar.